Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
Milton Packer(Baylor University Medical Center), Faı̈ez Zannad(Centre d’Investigation Clinique Innovation Technologique de Nancy), Martina Brueckmann, Javed Butler(Jackson Memorial Hospital), Gerasimos Filippatos(National and Kapodistrian University of Athens), Stuart Pocock(London School of Hygiene & Tropical Medicine), Hans‐Peter Brunner‐La Rocca(Inserm), Stefan Janssens(Maastricht University), Janet Schnee(Boehringer Ingelheim (United States)), Hiroyuki Tsutsui(Juntendo University), Jian Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), João Pedro Ferreira(Inserm), Stefan D. Anker(Charité - Universitätsmedizin Berlin), Tomoko Iwata(Boehringer Ingelheim (Germany)), Daniel Cotton(Boehringer Ingelheim (Germany)), Waheed Jamal(Inserm)
Cited by 135
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k